Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

Despite improved outcomes with current MM treatments, most patients (pts) will develop
refractory disease, highlighting the need for novel treatments. GPRC5D is an orphan …

Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM)
continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a …

Introduction: G protein-coupled receptor family C group 5 member D (GPRC5D) has limited
expression in normal human tissue but is highly expressed on malignant plasma cells …

8036 Background: Tal is a first-in-class BsAb targeting the novel antigen G protein–coupled
receptor family C group 5 member D. In MonumenTAL-1 (NCT03399799/NCT04634552), tal …

Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are
significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or …

Talquetamab (talquetamab-tgvs; TALVEY®), a humanized, bispecific G-protein coupled
receptor family C group 5 member D (GPRC5D)-directed CD3 T-cell engager, is being …

Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year
survival rate of approximately 60%. Despite advances in therapy, patients experience cycles …

T-cell–mediated approaches have shown promise in myeloma treatment. However, there
are currently a limited number of specific myeloma antigens that can be targeted, and …

Background: Despite advances in treatment, almost all pts with newly diagnosed multiple
myeloma (MM) eventually relapse and progression-free survival decreases with each …